Neuca

Neuca Goodwill

The Goodwill of Neuca (NEU.WA) as of Oct 23, 2026 is 1.04 B PLN. In the previous year, Goodwill was 1.00 B PLN — a change of 3.45% (higher).

Goodwill

1.04 BPLN

YoY

3.45%

Last updated:

Goodwill of Neuca is 2025 1.04 B PLN. Goodwill of Neuca was 2024 1.00 B PLN. It decreases by 3.45% higher compared to the previous year.

The Neuca Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2018
301.35 M PLN
Jan 1, 2019
309.21 M PLN
Jan 1, 2020
386.16 M PLN
Jan 1, 2021
644.14 M PLN
Jan 1, 2022
726.47 M PLN
Jan 1, 2023
975.21 M PLN
Jan 1, 2024
1.00 B PLN
Jan 1, 2025
1.04 B PLN
The Neuca Goodwill history
YEARGoodwillYoY
1.04 BPLN+3.45%
1.00 BPLN+2.81%
975.21 MPLN+34.24%
726.47 MPLN+12.78%
644.14 MPLN+66.80%
386.16 MPLN+24.89%
309.21 MPLN+2.61%
301.35 MPLN+21.24%
248.57 MPLN+8.68%
228.72 MPLN+16.83%
195.77 MPLN+45.95%
134.13 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Goodwill of Neuca is 1.04 B PLN in 2025.

Goodwill of Neuca changed from 1.00 B PLN to 1.04 B PLN, representing a 3.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Neuca since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Neuca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neuca

All Key Metrics — Neuca